Immunexpress Pty Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Athlomics Pty Ltd. (to 2017)
0
Ending by 2030
May 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Microbial markers and uses therefor (US 10,364,474) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Pathogen biomarkers and uses therefor (US 11,884,978) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,364,474 | Microbial markers and uses therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,167,511 | Biomarker identification In force · From the USPTO record | In force | From the USPTO record | |
| US 10,190,169 | Biomarker identification In force · From the USPTO record | In force | From the USPTO record | |
| US 10,975,437 | Use of C3AR1 as a biomarker in methods of treating inflammatory response syndromes In force · From the USPTO record | In force | From the USPTO record | |
| US 10,865,447 | Biomarker signature method, and apparatus and kits therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,047,010 | Biomarker signature method, and apparatus and kits thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,006,548 | Treating or inhibiting severe sepsis based on measuring defensin alpha 4 (DEFA4) expression In force · From the USPTO record | In force | From the USPTO record | |
| US 10,719,579 | Validating biomarker measurement In force · From the USPTO record | In force | From the USPTO record | |
| US 11,884,978 | Pathogen biomarkers and uses therefor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 9: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
12 no status recorded